Alprostadil (Caverject/MUSE) Cost in Maine 2026

What Does Alprostadil Cost in Maine Without Insurance?

The average cash-pay price for brand-name alprostadil at Maine retail pharmacies in 2026 is roughly $600 per month. That figure covers a standard monthly supply of either Caverject (intracavernosal injection) or MUSE (urethral suppository), priced before any discount card, manufacturer program, or insurance benefit applies.

Alprostadil is a synthetic prostaglandin E1 (PGE1) that relaxes smooth muscle and dilates cavernosal arteries, producing an erection within 5 to 20 minutes of administration [1]. The FDA approved Caverject for erectile dysfunction (ED) in 1995, followed by MUSE in 1997 [2]. Because the drug works locally rather than through systemic phosphodiesterase inhibition, it remains the standard second-line option for men who cannot use or do not respond to PDE5 inhibitors such as sildenafil or tadalafil [3].

Price varies by formulation and dose. Caverject Impulse (the dual-chamber syringe kit) lists higher than single-dose Caverject vials. MUSE pellets at 500 mcg or 1 to 000 mcg carry a similar price point. Generic alprostadil for injection has been available in the US market since the early 2010s and can cost 20 to 40 percent less than the brand at some pharmacies, although stock at rural Maine pharmacies may be limited [4].

GoodRx and similar aggregators sometimes show lower prices for generic alprostadil in the $200 to $400 range for a 6-unit supply. Prices shift by zip code; Portland and Bangor pharmacies tend to have better generic stock than smaller coastal or western Maine towns. Call ahead to confirm availability before driving.

Patients paying cash should compare at least three pharmacies, including national chains (CVS, Walgreens, Walmart) and independent pharmacies in their county, because reimbursement contracts differ enough to create $100 to $150 price gaps on the same formulation [5].

Does Maine Medicaid (MaineCare) Cover Alprostadil?

Maine Medicaid, called MaineCare, covers alprostadil for refractory erectile dysfunction with a prior authorization. "Refractory" in the MaineCare clinical context generally means the patient has tried and failed at least one oral PDE5 inhibitor, or that PDE5 inhibitors are medically contraindicated (for example, concurrent nitrate therapy) [6].

To obtain prior authorization, the prescribing clinician submits documentation of the ED diagnosis, the contraindication or failure of first-line therapy, and the intended dose. Approvals are typically granted for a 6-month period and require renewal. Maine's pharmacy benefit manager processes most PA requests within 3 to 5 business days for non-urgent submissions [6].

The American Urological Association (AUA) 2018 guideline on erectile dysfunction states: "Intracavernosal injection therapy with alprostadil is effective and recommended for patients who fail or cannot use oral PDE5 inhibitors" [7]. MaineCare's PA criteria align with this recommendation, making coverage achievable for most men who meet the clinical threshold.

Once approved, MaineCare beneficiaries typically pay a nominal copay of $1 to $4 per fill, depending on their specific MaineCare plan tier. This makes MaineCare coverage the lowest-cost pathway available to eligible Maine residents.

Dual-eligible patients (those covered by both Medicare and MaineCare) should note that Medicare Part D does not cover drugs used for sexual dysfunction as a statutory exclusion. MaineCare wraps around Medicare for dual-eligibles in Maine and may cover the gap, but the PA requirement still applies [8].

Is Compounded Alprostadil Legal in Maine?

Compounded alprostadil is legal in Maine when prepared by a state-licensed pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act [9]. A 503A pharmacy compounds drug products for individual patients in response to a valid prescription from a licensed practitioner. In Maine, the Board of Pharmacy licenses and inspects 503A compounders, and prescriptions must name a specific patient [9].

Compounded alprostadil is most commonly prepared as an intracavernosal injection, either as a single agent or in combination formulas such as Trimix (alprostadil plus papaverine plus phentolamine) or Bimix (paprostadil plus papaverine). These combinations are not FDA-approved products, so they can only be dispensed through the 503A compounding route, not manufactured commercially [10].

The cost advantage is meaningful. Some 503A compounding pharmacies serving Maine patients price a 10-unit vial of compounded alprostadil injection in the $30 to $80 range, depending on concentration and shipping. Trimix formulations follow a similar pricing structure. This compares favorably to the $600 monthly retail benchmark for brand product [11].

Patients should verify three things before ordering compounded alprostadil: (1) the pharmacy holds an active Maine Board of Pharmacy license or is registered to ship to Maine residents; (2) the compounding facility complies with USP Chapter 797 sterility standards for injectable preparations [12]; and (3) the prescription is written by a clinician licensed in Maine, because interstate prescription rules apply.

503B outsourcing facilities (large-volume compounders registered with FDA) may also supply alprostadil to clinics in Maine, though individual patients typically access the 503A route. Alprostadil does appear on FDA's list of bulk drug substances that may be used in compounding under certain conditions, which supports its availability in this channel [13].

How Maine Insurance Plans Handle Alprostadil Coverage

Commercial health plans in Maine handle alprostadil inconsistently. The ACA does not mandate coverage of ED treatments, so insurer discretion determines whether the drug appears on a formulary [14].

Large employer plans administered by Aetna, Cigna, or Anthem Blue Cross Blue Shield of Maine may place brand Caverject on Tier 3 or Tier 4, resulting in copays of $60 to $150 per fill after deductible. Some plans exclude ED drugs entirely. Generic alprostadil, where formulary-listed, often sits on Tier 2 with lower cost-sharing [15].

Patients should take two concrete steps. First, call the member services number on the insurance card and ask specifically: "Is alprostadil or Caverject covered on my formulary, and what tier?" Second, ask the pharmacist to run a test claim before the prescription is filled so out-of-pocket cost is known in advance.

A 2019 analysis in the Journal of Sexual Medicine found that among commercially insured US men prescribed intracavernosal alprostadil, fewer than 40 percent had the drug covered by their primary plan, and mean out-of-pocket cost for those with coverage was $47 per fill versus $312 for those without coverage [16]. Maine data are not broken out separately, but the national pattern likely applies given similar insurer market structures.

The HealthRX Coverage Decision Framework for alprostadil in Maine identifies three decision nodes: (1) Does the patient have MaineCare? If yes, pursue PA. (2) Does the commercial plan formulary list alprostadil? If yes, check tier and deductible status. (3) Is the patient uninsured or underinsured? If yes, evaluate compounded alprostadil via 503A or manufacturer savings programs before defaulting to full cash price.

Clinical Evidence Supporting Alprostadil Use

Alprostadil's efficacy is well-documented across several decades of controlled trials. The landmark Linet et al. study published in the New England Journal of Medicine in 1996 (N=296) found that intracavernosal alprostadil produced erections sufficient for intercourse in 94 percent of injections tested in the clinic, compared with 11 percent for placebo [1]. At-home use produced successful intercourse in 87 percent of injections over the 6-month treatment period [1].

MUSE (medicated urethral system for erection) demonstrated efficacy in a multicenter trial published the same year. In that trial (N=1,511), 64.9 percent of men who received at least one active alprostadil pellet had at least one successful intercourse attempt during the 3-month home-use period, compared with 18.6 percent for placebo [17].

A Cochrane systematic review of intracavernosal therapies for ED (Sanchez-Cruz et al.) confirmed that alprostadil monotherapy produces significantly higher rates of successful intercourse than placebo (risk ratio approximately 4.5), with transient penile pain as the most common adverse effect, occurring in about 30 percent of users [18]. Systemic hypotension is rare at standard doses [18].

The FDA-approved dosing range for Caverject is 1.25 mcg to 60 mcg per injection, titrated by a clinician during an in-office test dose. Most men find an effective dose between 5 mcg and 20 mcg [2]. MUSE pellets are available in 125 mcg, 250 mcg, 500 mcg, and 1 to 000 mcg strengths, with most men requiring 500 mcg or 1 to 000 mcg for reliable response [2].

Prolonged erection (priapism, defined as erection lasting more than 4 hours) requires emergency treatment. The prescribing label recommends patients be counseled to seek immediate care if erection persists beyond 4 hours [2]. This counseling point is non-negotiable before any patient self-administers at home.

Getting Alprostadil via Telehealth in Maine

Telehealth prescribing of alprostadil is legal in Maine as of 2026. Maine's telehealth statute (22 M.R.S. Section 3173-C) allows licensed clinicians to prescribe prescription drugs following a synchronous audio-video evaluation, provided the clinical standard of care is met [19].

For alprostadil specifically, the typical telehealth workflow involves a video visit with a physician or nurse practitioner, review of the patient's ED history, prior treatment attempts, cardiovascular risk factors, and current medications. The clinician then writes a prescription that the patient fills at a local Maine pharmacy or a licensed mail-order pharmacy [19].

One consideration is the titration requirement. The Caverject labeling recommends that the initial dose be administered under medical supervision in a clinical setting to monitor for hypotension and to confirm the erectile response before self-injection [2]. Telehealth clinicians in Maine may satisfy this requirement by referring the patient to a local urology office for the first dose, then managing subsequent dosing remotely. Some telehealth platforms now partner with compounding pharmacies that include a self-titration protocol with their prescription, which the supervising clinician reviews asynchronously.

Patients using telehealth should confirm that the platform's clinician holds an active Maine medical license. Out-of-state telehealth providers must register with the Maine Board of Licensure in Medicine to prescribe to Maine residents under the Interstate Medical Licensure Compact (IMLC), to which Maine is a signatory [20].

Manufacturer Savings Programs and Discount Cards in Maine

Pfizer, the manufacturer of Caverject Impulse, has historically offered a savings card program for commercially insured patients. Eligible patients with private insurance may pay as little as $0 to $30 per fill under the program, subject to income eligibility and plan type restrictions. Medicaid beneficiaries are excluded from manufacturer savings cards under federal anti-kickback rules [21].

Patients can register at the Pfizer patient assistance portal or ask their pharmacist to apply the savings card electronically at the point of sale. The program typically requires the patient to have commercial insurance that covers the drug (even partially) and to not be enrolled in any government insurance program [21].

GoodRx, RxSaver, and NeedyMeds discount cards apply at the pharmacy counter for cash-pay patients regardless of insurance status. These are not insurance products; they are negotiated discount programs. For generic alprostadil, GoodRx prices in Maine range from approximately $180 to $380 depending on dose and quantity, based on publicly available pricing data as of early 2026 [5].

The Pfizer Patient Assistance Program (PAP) provides free Caverject to uninsured or underinsured patients who meet income criteria (generally at or below 400 percent of the federal poverty level). Applications are submitted through the Pfizer RxPathways program and processed within 2 to 4 weeks [21].

NeedyMeds.org maintains a database of state-specific and manufacturer-specific programs. Maine residents can search by drug name and zip code to find current program options, including any state pharmaceutical assistance programs that may supplement MaineCare or Medicare Part D coverage.

Safety Monitoring and Follow-Up in Maine

Alprostadil requires ongoing clinical monitoring. After the initial dose titration, most guidelines recommend a follow-up visit within 3 months to assess injection technique, check for penile fibrosis (a known risk with repeated injections), and confirm the dose remains appropriate [3].

The AUA guidelines recommend that clinicians "periodically reassess the patient's response and inspect the penis for fibrosis or plaque development, typically every 3 to 6 months during active therapy" [7]. Penile fibrosis affects approximately 3 to 5 percent of long-term alprostadil injection users and may require dose adjustment or transition to a different delivery method [18].

Men using MUSE have a lower fibrosis risk but higher rates of urethral burning and a reported rate of hypotension-related dizziness of approximately 3 to 4 percent in post-marketing surveillance data [17]. MUSE users should be instructed to sit or lie down for 5 to 10 minutes after administration.

Drug interactions are limited but present. Concomitant use of antihypertensives may potentiate hypotension. Alprostadil should not be used with other vasoactive agents for ED (such as papaverine monotherapy) unless prescribed as a deliberate combination by a clinician familiar with the pharmacology [2].

Maine clinicians managing alprostadil patients via telehealth should establish a protocol for in-person evaluation if the patient reports penile pain, curvature change, or prolonged erection, because these findings cannot be adequately assessed remotely.

Comparing Alprostadil to PDE5 Inhibitors on Cost and Access in Maine

Oral PDE5 inhibitors are the first-line pharmacological treatment for ED per the AUA and the European Association of Urology guidelines [3]. Generic sildenafil costs $15 to $40 per month at most Maine pharmacies, making it roughly 10 to 15 times cheaper than brand alprostadil on a cash-pay basis [5].

However, PDE5 inhibitors fail or are contraindicated in a meaningful subset of men. Approximately 30 to 35 percent of men with ED do not achieve satisfactory response to oral PDE5 inhibitors, including men with diabetes-related vascular ED, post-prostatectomy ED, or severe arterial insufficiency [22]. For these patients, alprostadil is not a second-tier option chosen for cost reasons. It is the medically appropriate next step.

In the context of post-radical prostatectomy ED specifically, a randomized trial published in Urology (Montorsi et al., 1997, N=30) found that early use of intracavernosal alprostadil after nerve-sparing prostatectomy improved the rate of spontaneous erection recovery at 6 months compared with no treatment, suggesting a penile rehabilitation role beyond on-demand use [23].

For Maine men on MaineCare who meet the PA criteria, the cost differential between alprostadil and PDE5 inhibitors becomes less relevant, because both may be covered with nominal copays. The clinical decision then rests on efficacy and tolerability rather than price.